Ferring Pharmaceuticals

This study tested a treatment called RBX2660 (REBYOTA) for people with recurrent Clostridioides difficile infection. The treatment is made from healthy human stool bacteria and was given during a colonoscopy. The goal was to see if this delivery method is safe and works well. For…

This completed Phase 3 trial compared two fertility drugs—follitropin delta (Rekovelle) and follitropin alfa (Gonal-F)—in 301 Chinese women undergoing IVF. The goal was to see which starting dose leads to the best number of eggs retrieved. Participants received daily injections f…

This study looked at the long-term safety of the drug degarelix in 57 men with prostate cancer. Participants received a monthly injection of degarelix for up to 5 years. The goal was to monitor side effects, such as changes in blood pressure, pulse, weight, and liver function.

This observational study followed 145 adults who received REBYOTA™ to prevent another Clostridioides difficile infection (CDI) after completing antibiotics. Researchers collected information from medical records over 6 months to see how many people stayed infection-free. The goal…

This survey follows people who use the REKOVELLE pen, which contains the hormone follitropin delta, to stimulate the ovaries during assisted reproduction like IVF or ICSI. The goal is to track how often side effects occur when the drug is used in everyday clinical practice. Resea…

This study looked at medical records from Denmark, Sweden, and Germany to see how safe NOCDURNA is for people who wake up often at night to urinate due to a condition called nocturnal polyuria. Researchers tracked serious side effects like low sodium levels in the blood. The stud…

This study observed 201 women in Nordic countries and Switzerland who were using the fertility drug REKOVELLE® for the first time during IVF or ICSI. Researchers tracked how doctors prescribed the drug, including dose adjustments and use of a dosing app, to understand real-world …